Live News EQUITY FLASH L impact Nov 05, 2026, 06:15 AM UTC Camurus Begins Dosing in Phase 2b Obesity Study of CAM2056 Camurus has begun dosing in a Phase 2b study of CAM2056 for obesity and overweight. SquawkNews Desk